WARNING: ASTHMA-RELATED DEATH

Long-acting beta2-adrenergic agonists (LABA), such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death.

...continue reading

Indications for ADVAIR DISKUS 250/50 for COPD

  • ADVAIR DISKUS 250/50 is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS 250/50 is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
  • ADVAIR DISKUS 250/50 twice daily is the only approved dosage for the treatment of COPD because an efficacy advantage of the higher strength ADVAIR DISKUS 500/50 over ADVAIR DISKUS 250/50 has not been demonstrated.
  • ADVAIR DISKUS is NOT indicated for the relief of acute bronchospasm.

An ICS/LABA (inhaled corticosteroid/long-acting beta2-agonist) for the maintenance treatment of COPD (Chronic Obstructive Pulmonary Disease) including chronic bronchitis and/or emphysema.

References

"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"View all references

820125R0 May 2017